ElectroCore
| Company type | Public |
|---|---|
| Industry | Medical technology |
| Founded | 2005 |
| Founder | JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, Peter Staats, MD |
| Headquarters | Basking Ridge , United States |
Key people | Daniel S. Goldberger (CEO) |
| Products | gammaCore, Truvaga |
electroCore, Inc. (Nasdaq: ECOR) operates as a medical technology firm situated in Basking Ridge, New Jersey. Established in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, the enterprise specializes in devices for non-invasive stimulation of the vagus nerve. The company is currently led by CEO Daniel S. Goldberger.
The company's primary offering is gammaCore, a non-invasive vagus nerve stimulator that has received regulatory approval for the treatment of cluster headaches and is commercially available.
History
Launched in 2005 through the collaboration of JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, electroCore transitioned to a public company in 2018 via an initial public offering that raised $78 million.
In March 2020, electroCore entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor, securing potential funding up to $25 million.
gammaCore Sapphire CV
The FDA authorized emergency use of gammaCore Sapphire CV in July 2020. This vagus nerve stimulation device aims to alleviate asthma exacerbations in patients experiencing respiratory distress possibly linked to COVID-19.
Truvaga
Truvaga represents another vagus nerve stimulation device within electroCore’s expanding portfolio focused on neuromodulation treatment options.